Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF (PULSED AF)

JRCT ID: jRCT2052210035

Registered date:10/06/2021

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: drug refractory recurrent symptomatic paroxysmal or persistent atrial fibrillation
• Date of first enrollment: 10/06/2021
• Target sample size: 400
• Countries of recruitment: United States of America,Japan,Canada,Japan,Australia,Japan,Austria,Japan,Belgium,Japan,France,Japan,Netherlands,Japan,UK,Japan,Italy,Japan,Spain,Japan
• Study type: Interventional
• Intervention(s): Perform the pulmonary vein isolation procedure using the MDT-1219 PFA System with the MDT-1219 cardiac ablation catheter.

Outcome(s)

Primary Outcome

- safety
Demonstrate an acceptable safety profile of PVI ablation with the MDT-1219 PFA System
- effectiveness
Demonstrate an acceptable chronic effectiveness of PVI ablation with the MDT-1219 PFA System, based on freedom from treatment failure

• Secondary Outcome: Assess changes in quality of life

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: <= 80age old
• Gender: Both

Include criteria

1. Failure of at least one AAD (class I or III) for AF as evidenced by recurrent symptomatic AF, or intolerable side effects due to AAD.
2. A diagnosis of recurrent symptomatic paroxysmal or persistent AF:
a. Symptomatic paroxysmal AF, which is defined as AF that terminates spontaneously or with intervention within 7 days of onset, documented by the following:
1) Physicians note indicating at least 2 symptomatic paroxysmal AF episodes occurring within 6 months prior to enrollment; and
2) at least 1 ECG documented AF episode from any form of rhythm monitoring within 12 months prior to enrollment
OR
b. Symptomatic persistent AF, which is defined as continuous AF sustained beyond 7 days and less than 1 year, documented by the following:
1) physicians note indicating at least 1 symptomatic persistent AF episode occurring within 6 months prior to enrollment; and
2) any 24-hour continuous ECG recording documenting continuous AF within 6 months prior to enrollment;
OR
2 ECGs from any form of rhythm monitoring taken at least 7 days apart, both showing continuous AF within 6 months prior to enrollment
3. Age 18 through 80 years old (or older than 18 if required by local law)

Exclude criteria

1.Long-standing persistent AF (continuous AF that is sustained >12 months)
2.Left atrial diameter > 5.0 cm (anteroposterior)
3.Prior left atrial ablation or surgical procedure (including left atrial appendage closures)
4.Planned LAA closure procedure or implant of a permanent pacemaker, biventricular pacemaker, loop recorder/insertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function) for any time during the follow-up period
5.Patient who is not on oral anticoagulation therapy for at least 3 weeks prior to the ablation procedure
6.Presence of a permanent pacemaker, biventricular pacemaker, loop recorder/insertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function)
7.Presence of any pulmonary vein stents
8.Presence of any pre-existing pulmonary vein stenosis
9.Pre-existing hemidiaphragmatic paralysis
10.Presence of any cardiac valve prosthesis
11.Moderate to severe mitral valve stenosis
12.More than moderate mitral regurgitation (i.e., 3+ or 4+ MR)
13.Any cardiac surgery, myocardial infarction, PCI / PTCA or coronary artery stenting which occurred during the 3-month interval preceding the consent date
14.Unstable angina
15.NYHA Class III or IV congestive heart failure or documented left ventricular ejection fraction (LVEF) less than or equal to 35% measure by acceptable cardiac testing (e.g. TTE)
16.Primary pulmonary hypertension
17.Rheumatic heart disease
18.Thrombocytosis, thrombocytopenia
19.Any condition contraindicating chronic anticoagulation
20.Active systemic infection
21.Hypertrophic cardiomyopathy
22.Known reversible causes of AF, including but not limited to uncontrolled hyperthyroidism, severe untreated obstructive sleep apnea, and acute alcohol toxicity
23.Any cerebral ischemic event (strokes or TIAs) which occurred during the 6-month interval preceding the consent date
24.History of thromboembolic event within the past 6 months or evidence of intracardiac thrombus at the time of the procedure
25.Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence
26.Patient with life expectancy that makes it unlikely 12 months of follow-up will be completed
27.Current or anticipated participation in any other clinical trial of a drug, device or biologic during the duration of the study not pre-approved by Medtronic
28.Known allergies or hypersensitivities to adhesives
29.Unwilling or unable to comply fully with study procedures and follow-up
30.Unable to provide own informed consent

Related Information

• Primary Sponsor: Shiomitsu Aki
• Secondary ID(s): NCT04198701